Einführung und Zusammenfassung

Schröder, Helmut; Thürmann, Petra A.; Telschow, Carsten; Schröder, Melanie; Busse, Reinhard

doi:10.1007/978-3-662-66041-6_1

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, the 2020 current additional benefit assessments for ceritinib and brigatinib in individual indications were considerably better than those for alectinib and lorlatinib. This shows that the high drug prices of the protein kinase inhibitors create economic incentives for the pharmaceutical companies (pC), which lead to more me-too drugs being introduced to market instead of developing drugs with new mechanisms of action (Schröder et al 2021).…”

Section: Salesmentioning

confidence: 99%

“…In fact, however, the costs for research and development are significantly lower than claimed by the company (Schröder et al 2021). In many cases, the high costs of oncology drugs can therefore neither be justified by high expenditures for research and development nor by any outstanding additional clinical benefit.…”

Section: The Case Of Palbociclibmentioning

confidence: 99%

“…Thus, with the scientific information available to us, there is no scheme why an individual protein kinase inhibitor is promoted or not. Therefore, it should be noted that the high drug costs associated with protein kinase inhibitors attract economic interest among pC to make as much profit as possible (Schröder et al 2021).…”

Section: Advertisementsmentioning

confidence: 99%

See 2 more Smart Citations

Critical analysis of the prescription and evaluation of protein kinase inhibitors for oncology in Germany

Obst

Seifert

2023

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

The prices of oncology drugs have been rising progressively in recent years. Despite accounting for only a small share of prescriptions, oncology drugs are the most expensive drugs on the market. However, the association between drug price and clinical benefit often remains questionable. Therefore, we set out to analyze the development of prescription and benefit assessment of protein kinase inhibitors. We identified 20 protein kinase inhibitors with oncological indications that were newly approved by the European Medicines Agency (EMA) between 2015 and 2019, based on the Arzneiverordnungsreport (AVR, Drug Prescription Report). For these 20 drugs, the number of prescriptions, sales, defined daily dose (DDD), and DDD costs were identified for the year of approval and for 2020, respectively, based on data from the Wissenschaftliches Institut der Ortskrankenkassen (WIdO, Scientific Institute of the General Local Health Insurance Fund, AOK). Moreover, the additional benefit assessments by the Gemeinsamer Bundesausschuss (GBA, Federal Joint Committee) were considered for each drug. It is shown that the share of a drug in prescriptions, sales, and DDD does not correlate with the clinical benefit of the drug as measured by the additional benefit assessment by the GBA. Lastly, the advertisement pattern of protein kinase inhibitors in a representative oncology journal does not correlate with drug benefit. In conclusion, the immense costs of oncology drugs are therefore largely caused by drugs for which no additional benefit has been proven by the GBA. In order to ensure the long-term stability of health care systems, price-regulation measures are urgently needed, especially for drugs whose additional benefit has not been proven.

show abstract

Section: Salesmentioning

confidence: 99%

Section: The Case Of Palbociclibmentioning

confidence: 99%